Of interest, <i>PD-L1</i>, <i>PD-L2</i> and <i>JAK2</i> amplification is a characteristic of Hodgkin lymphoma, which is exquisitely sensitive to nivolumab. Here, JAK2 is linked to Hodgkins lymphoma.